Kisspeptin Results Timeline: What Studies Measured, and When

When people ask about a "kisspeptin timeline," they are usually asking a question the published literature answers in an unexpected way. The kisspeptin human literature is dominated by acute administration studies — participants attended a research visit, received the peptide intravenously, and had blood drawn and questionnaires administered across minutes to a few hours. Multi-week dosing trials with week-4, week-8 and week-12 outcome tables, the format familiar from drug development, are largely absent from the verified evidence summarised here. This page describes what was measured and when, and flags clearly where human timeline data does not exist.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, hormone symptom or investigational compound. Nothing here describes a protocol, a schedule or an expected personal outcome. For background on the peptide itself, see the overview at /learn/kisspeptin/.

The dominant timescale in human studies: minutes to hours

Kisspeptin signalling sits upstream of gonadotropin-releasing hormone, so the physiological events researchers chose to sample are fast. In a 2025 study published in The Journal of Clinical Endocrinology and Metabolism, researchers reported that kisspeptin administration stimulated reproductive hormones in humans but did not affect anxiety measures (PMID 40036336). That design captures the shape of most of this field: a hormonal endpoint that moves within a single session, paired with a psychological endpoint assessed during the same visit rather than after weeks of repeated exposure.

A second 2025 report, in the European Journal of Endocrinology, described sex-dependent increases in oxytocin levels in response to intravenous kisspeptin in humans (PMID 39965102). Again, the informative unit of time was the sampling interval within an infusion study, not a week or a month. Taken together, these two human reports establish that the measurable acute signal in this literature is neuroendocrine — hormones in blood — and that the studies were built around within-visit sampling rather than longitudinal follow-up (PMID 40036336, PMID 39965102).

What "sex-dependent" implies for reading a timeline

The oxytocin finding matters for anyone trying to generalise a single curve to all participants, because researchers reported that the oxytocin response to intravenous kisspeptin differed by sex (PMID 39965102). A timeline drawn from one group's averages is therefore not automatically transferable to another group, and averaged response curves in small mechanistic studies should not be read as individual trajectories.

Where multi-week human kisspeptin data is thin — stated plainly

There is no week-by-week human efficacy trial of kisspeptin in the verified citation set for this page. The human entries available here are acute administration work on reproductive hormones and anxiety (PMID 40036336) and on oxytocin (PMID 39965102), plus a 2024 randomised trial in Medicine that examined kisspeptin expression levels in patients with placenta previa (PMID 38996103). The last of these measured endogenous kisspeptin as a biological marker in a clinical population rather than tracking outcomes after repeated administration, which is a different question again.

The practical consequence is that phrases like "results at 4 weeks" or "by week 12" have no anchor in the human kisspeptin literature summarised here. Claims of that kind, when they appear elsewhere, are typically extrapolations from acute physiology (PMID 40036336) or from animal work, and this page keeps those categories separate.

Longer timelines in preclinical models — clearly labelled as animal and cell work

Longer-horizon kisspeptin data in this citation set comes from preclinical pharmacology. A 2024 study in Phytomedicine reported that Jiawei Buzhong Yiqi Decoction attenuated polycystic ovary syndrome through regulation of the kisspeptin–GPR54–AKT–SHBG system (PMID 39116604). That is a mechanism study in a disease model, and the kisspeptin axis appears there as a pathway that changed alongside the intervention — not as an administered peptide with a dose-by-week human schedule. Preclinical timelines run on model-specific calendars (oestrous cycles, induction periods, tissue harvest points) that do not convert into human weeks.

When reading any preclinical timeline, three translation gaps recur: species differences in reproductive cycling, route and exposure differences, and endpoint differences — histology and receptor expression in animals versus symptoms and hormone panels in people. The kisspeptin–GPR54 pathway result illustrates the gap well, because the readouts were molecular and tissue-level rather than clinical (PMID 39116604).

Adjacent pathway drugs that were studied over weeks

Because kisspeptin neurons in the arcuate nucleus co-express neurokinin B and dynorphin, drugs targeting neurokinin receptors have been tested in humans on conventional multi-week trial calendars, and those trials show what a genuine week-scale design looks like in this neighbourhood of physiology. A randomised controlled trial published in 2021 evaluated the neurokinin 3 receptor antagonist fezolinetant for treatment of polycystic ovary syndrome (PMID 34000049). Separately, researchers reported that elinzanetant (NT-814), a neurokinin 1,3 receptor antagonist, reduced estradiol and progesterone in healthy women (PMID 33624806).

These are not kisspeptin studies and should not be read as a proxy timeline for kisspeptin itself. They are included because they demonstrate that the wider KNDy pathway can be probed with repeated-dosing designs and endocrine endpoints measured across a treatment period (PMID 34000049, PMID 33624806), whereas the kisspeptin administration work in the same set stayed within single visits (PMID 39965102).

Timepoints measured across the cited literature

Why background physiology sets the ceiling on any timeline

Kisspeptin sits inside a system that changes on much longer timescales than any infusion study. A 2025 review in Frontiers in Endocrinology described mechanisms and immediate consequences of reproductive ageing in biological females (PMID 41019345), and a 2023 review in BMJ Medicine covered polycystic ovary syndrome pathophysiology and therapeutic opportunities (PMID 37859784). At the other end of life, reviews of central precocious puberty traced the condition from genetics to treatment (PMID 30086862), and a 2022 review examined genetic factors in precocious puberty (PMID 34665958).

Those reviews are relevant to timeline questions because the underlying reproductive axis has its own trajectory — pubertal, cyclical and age-related — that an acute stimulus is measured against rather than replacing (PMID 41019345, PMID 30086862).

Confounders that move on their own schedule

Two further reviews illustrate how much of the axis is already in motion before anything is administered. A 2025 review in Stress examined the impact of stress on the menstrual cycle and ovulation (PMID 39862134), and a 2020 review in Human Reproduction Update covered perfluoroalkyl and polyfluoroalkyl substances and their effects on the ovary (PMID 32476019). Both describe influences that operate over cycles, months or years, which is one reason short administration studies use within-session sampling and controlled conditions rather than open-ended follow-up (PMID 39862134).

Adverse Events Across Timepoints: What Studies Report

The verified citation set for this page does not include a dedicated long-term safety study of administered kisspeptin, and that absence should be stated rather than filled in. What is available is limited and short-horizon: researchers reported that kisspeptin administration stimulated reproductive hormones but did not affect anxiety in humans (PMID 40036336), and the oxytocin study characterised a hormonal response rather than a tolerability outcome (PMID 39965102).

For adjacent pathway drugs, endocrine changes were themselves measured outcomes: researchers reported that elinzanetant reduced estradiol and progesterone in healthy women (PMID 33624806). Hormone-lowering effects of that kind are pharmacological findings from a specific compound and study population, and they do not describe kisspeptin. No adverse-event frequency, severity grading or long-term event rate for kisspeptin is asserted here, because the cited papers do not supply one (PMID 40036336).

How to read a kisspeptin timeline claim critically

• Check whether the study administered kisspeptin or measured it. The placenta previa trial examined kisspeptin expression levels in patients (PMID 38996103), which is a marker question, not an effect-over-time question.
• Check the species. Pathway-level findings such as kisspeptin–GPR54–AKT–SHBG regulation came from a preclinical PCOS model (PMID 39116604).
• Check the molecule. Fezolinetant is a neurokinin 3 receptor antagonist studied in PCOS (PMID 34000049), not kisspeptin.
• Check the endpoint. Hormone concentrations moved within sessions in human work (PMID 39965102); symptom endpoints over weeks were not part of those designs.
• Check the population. Reviews of precocious puberty (PMID 34665958) and reproductive ageing (PMID 41019345) describe very different baseline axes.

Bottom line on timing in the published record

The honest summary is narrow: human kisspeptin research in this set measured neuroendocrine responses inside single research visits, reporting reproductive hormone stimulation without an anxiety effect (PMID 40036336) and sex-dependent oxytocin increases after intravenous administration (PMID 39965102). Week-scale and month-scale human evidence in the same therapeutic neighbourhood belongs to different molecules, such as the neurokinin 3 receptor antagonist trialled in PCOS (PMID 34000049). Anything presented as a kisspeptin week-by-week expectation chart is going beyond what these papers measured.

References

• Kisspeptin Administration Stimulates Reproductive Hormones but Does Not Affect Anxiety in Humans (The Journal of Clinical Endocrinology and Metabolism, 2025)
• Sex-dependent increases in oxytocin levels in response to intravenous kisspeptin in humans (European Journal of Endocrinology, 2025)
• Kisspeptin expression levels in patients with placenta previa: A randomized trial (Medicine, 2024)
• Jiawei Buzhong Yiqi Decoction attenuates polycystic ovary syndrome through regulating kisspeptin-GPR54-AKT-SHBG system (Phytomedicine, 2024)
• Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome (The Journal of Clinical Endocrinology and Metabolism, 2021)
• Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women (The Journal of Clinical Endocrinology and Metabolism, 2021)
• Polycystic ovary syndrome: pathophysiology and therapeutic opportunities (BMJ Medicine, 2023)
• Reproductive aging in biological females: mechanisms and immediate consequences (Frontiers in Endocrinology, 2025)
• Central precocious puberty: From genetics to treatment (Best Practice & Research Clinical Endocrinology & Metabolism, 2018)
• Genetic factors in precocious puberty (Clinical and Experimental Pediatrics, 2022)
• The silent pandemic of stress: impact on menstrual cycle and ovulation (Stress, 2025)
• Perfluoroalkyl and polyfluoroalkyl substances (PFAS) and their effects on the ovary (Human Reproduction Update, 2020)